{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:42:22Z","timestamp":1794048142079,"version":"4.8.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014554","name":"Janssen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.euroneuro.2024.11.013","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T09:15:39Z","timestamp":1735118139000},"page":"62-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"92","author":[{"given":"Nicholas","family":"Fabiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1642-8349","authenticated-orcid":false,"given":"Carl","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-5203","authenticated-orcid":false,"given":"Mikkel","family":"H\u00f8jlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.013_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/28.1.1","article-title":"Traditional reviews, meta-analyses and pooled analyses in epidemiology","volume":"28","author":"Blettner","year":"1999","journal-title":"Int. J. Epidemiol."},{"issue":"4","key":"10.1016\/j.euroneuro.2024.11.013_bib0002","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.013_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res. Synth. Methods"},{"issue":"8","key":"10.1016\/j.euroneuro.2024.11.013_bib0004","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.013_bib0005","first-page":"116","article-title":"Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials","volume":"22","author":"Burschinski","year":"2023","journal-title":"World Psychiatry Off J World Psychiatr Assoc WPA"},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.013_bib0006","first-page":"38","article-title":"Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia","volume":"19","author":"Carbon","year":"2014","journal-title":"CNS. Spectr."},{"issue":"3","key":"10.1016\/j.euroneuro.2024.11.013_bib0007","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: a Meta-Analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2024.11.013_bib0008","first-page":"330","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry Off J World Psychiatr Assoc WPA"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-2-1","article-title":"Simpson's paradox and calculation of number needed to treat from meta-analysis","volume":"2","author":"Cates","year":"2002","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102294","article-title":"Life expectancy and years of potential life lost in people with mental disorders: a systematic review and meta-analysis","volume":"65","author":"Chan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0011","unstructured":"Deeks, J.J., Higgins, J.P.T., Altman, D.G., Joanne E McKenzie, J.E., Areti Angeliki Veroniki, A.A., on behalf of the Cochrane Statistical Methods Group, 2024. Chapter 10: Analysing data and undertaking meta-analyses. Accessed October 6, 2024. https:\/\/training.cochrane.org\/handbook\/current\/chapter-10."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0012","unstructured":"COBENFY U.S. Prescribing Information. https:\/\/packageinserts.bms.com\/pi\/pi_cobenfy.pdf."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.013_bib0013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","article-title":"Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophr Heidelb Ger"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.013_bib0014","first-page":"119","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry Off J World Psychiatr Assoc WPA"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.013_bib0015","first-page":"149","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry Off J World Psychiatr Assoc WPA"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative Symptoms in Schizophrenia: a Review and Clinical Guide for Recognition, Assessment, and Treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.013_bib0017","first-page":"248","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatr. Off J World Psychiatr Assoc WPA"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0018","unstructured":"Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. www.covidence.org."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0019","article-title":"The impact of weight gain on antipsychotic nonadherence or discontinuation: a systematic review and meta-analysis","volume":"17","author":"De","year":"2024","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"Dibonaventura","year":"2012","journal-title":"BMC. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2024.11.013_bib0021","first-page":"448","article-title":"Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates","volume":"45","author":"Diniz","year":"2023","journal-title":"Rev Bras Psiquiatr Sao Paulo Braz 1999"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euroneuro.2024.04.007","article-title":"Single-arm meta-analysis of drug response in placebo-controlled versus active-controlled antipsychotic drug trials in schizophrenia","volume":"84","author":"Dong","year":"2024","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"issue":"7109","key":"10.1016\/j.euroneuro.2024.11.013_bib0023","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0024","article-title":"Antipsychotic Drugs and Cognitive Function: a Systematic Review and Pairwise Network Meta-Analysis","author":"Feber","year":"2024","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euroneuro.2022.08.001","article-title":"Ethical considerations for precision psychiatry: a roadmap for research and clinical practice","volume":"63","author":"Fusar-Poli","year":"2022","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"issue":"7650","key":"10.1016\/j.euroneuro.2024.11.013_bib0026","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2024.08.001","article-title":"Efficacy of KarXT on negative symptoms in acute schizophrenia: a post hoc analysis of pooled data from 3 trials","volume":"274","author":"Horan","year":"2024","journal-title":"Schizophr. Res."},{"issue":"10202","key":"10.1016\/j.euroneuro.2024.11.013_bib0028","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0031","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41398-023-02400-x","article-title":"Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system","volume":"13","author":"Jones","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0032","unstructured":"Kaul I., Correll C., Sawchak S., Miller A., Paul S., Brannan S. KarXT (Xanomeline\u2013Trospium) demonstrates broad efficacy in people with schizophrenia across a wide range of demographic subgroups: pooled results from the 3 randomized, double-blind, placebo-controlled emergent trials. Published online December 3, 2023."},{"issue":"10422","key":"10.1016\/j.euroneuro.2024.11.013_bib0033","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.euroneuro.2024.11.013_bib0034","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: a Randomized Clinical Trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0035","article-title":"FDA approves first schizophrenia drug with new mechanism of action since 1950s","volume":"26","author":"Kingwell","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.euroneuro.2024.11.013_bib0036","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"10.1016\/j.euroneuro.2024.11.013_bib0037","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2024.11.013_bib0038","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","volume":"268","author":"Krause","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.euroneuro.2024.11.013_bib0039","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14656566.2024.2334424","article-title":"Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review","volume":"25","author":"Leber","year":"2024","journal-title":"Expert. Opin. PharmacOther"},{"issue":"3","key":"10.1016\/j.euroneuro.2024.11.013_bib0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra1801490","article-title":"Psychotic Disorders","volume":"379","author":"Lieberman","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0041","unstructured":"NCT03697252. A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia. Published online 2018. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01663898\/full."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0042","unstructured":"NCT04659161. A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2). Published online 2020. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02206254\/full."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0043","unstructured":"NCT04738123. A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3). Published online 2021. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02234755\/full."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0044","unstructured":"NCT05145413. A study to assess efficacy and safety of adjunctive KarXT in subjects with inadequately controlled symptoms of schizophrenia. Published online 2021. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-02353514\/full."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0045","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.euroneuro.2024.11.013_bib0046","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","article-title":"Muscarinic Receptor Activators as Novel Treatments for Schizophrenia","volume":"96","author":"Paul","year":"2024","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2024.11.013_bib0047","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2005.07.015","article-title":"Treatment of cognitive dysfunction in schizophrenia","volume":"27","author":"Peuskens","year":"2005","journal-title":"Clin. Ther."},{"issue":"11","key":"10.1016\/j.euroneuro.2024.11.013_bib0049","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S2215-0366(23)00262-6","article-title":"Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development","volume":"10","author":"Pillinger","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.013_bib0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0051","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jclinepi.2015.08.013","article-title":"An algorithm was developed to assign GRADE levels of evidence to comparisons within systematic reviews","volume":"70","author":"Pollock","year":"2016","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.013_bib0052","doi-asserted-by":"crossref","first-page":"14490","DOI":"10.4088\/JCP.22r14490","article-title":"Comparative Effects of 11 Antipsychotics on Weight Gain and Metabolic Function in Patients With Acute Schizophrenia: a Dose-Response Meta-Analysis","volume":"84","author":"Sab\u00e9","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0053","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.euroneuro.2021.07.003","article-title":"Precision psychiatry: complex problems require complex solutions","volume":"52","author":"Salagre","year":"2021","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0054","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","article-title":"Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study","volume":"12","author":"Sauder","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.013_bib0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.euroneuro.2013.09.010","article-title":"Stratified medicine for mental disorders","volume":"24","author":"Schumann","year":"2014","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.euroneuro.2024.11.013_bib0056","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2024.11.013_bib0057","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"10\u201312","key":"10.1016\/j.euroneuro.2024.11.013_bib0058","first-page":"43","article-title":"Xanomeline and Trospium: a Potential Fixed Drug Combination (FDC) for Schizophrenia\u2014A Brief Review of Current Data","volume":"19","author":"Singh","year":"2022","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0059","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.euroneuro.2024.07.009","article-title":"Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: a subanalysis of a systematic review and meta-analysis with meta-regression of moderators","volume":"88","author":"Solmi","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.euroneuro.2024.11.013_bib0060","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14740338.2024.2396396","article-title":"Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review","volume":"23","author":"Solmi","year":"2024","journal-title":"Expert. Opin. Drug Saf."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0061","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0062","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.euroneuro.2024.11.013_bib0063","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.013_bib0064","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/schbul\/sbab087","article-title":"Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: results From a Nationwide, Within-subject Design Study","volume":"48","author":"Solmi","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0065","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.euroneuro.2024.11.013_bib0066","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1176\/ps.2008.59.5.500","article-title":"What CATIE Found: results From the Schizophrenia Trial","volume":"59","author":"Swartz","year":"2008","journal-title":"Psychiatr Serv Wash DC"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0067","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12991-020-00292-5","article-title":"The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey","volume":"19","author":"Tandon","year":"2020","journal-title":"Ann. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.013_bib0068","first-page":"166","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psychiatry Off J World Psychiatr Assoc WPA"},{"issue":"3","key":"10.1016\/j.euroneuro.2024.11.013_bib0069","first-page":"339","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry Off J World Psychiatr Assoc WPA"},{"issue":"null","key":"10.1016\/j.euroneuro.2024.11.013_bib0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/PPA.S124658","article-title":"Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness","volume":"11","author":"Velligan","year":"2017","journal-title":"Patient. Prefer. Adherence"},{"issue":"3","key":"10.1016\/j.euroneuro.2024.11.013_bib0071","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14316","article-title":"Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study","volume":"83","author":"Weiden","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0072","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.schres.2024.09.023","article-title":"A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia","volume":"274","author":"Wright","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0073","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euroneuro.2023.03.015","article-title":"Antipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose-response meta-analysis","volume":"72","author":"Wu","year":"2023","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.euroneuro.2024.11.013_bib0075","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends. Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2024.11.013_bib0076","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2021.08.013","article-title":"Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis","volume":"237","author":"Zhu","year":"2021","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.euroneuro.2024.11.013_bib0077","first-page":"2435","article-title":"Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial","volume":"171","author":"Zinner","year":"2004","journal-title":"J. Urol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24007879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24007879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T11:51:27Z","timestamp":1740397887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X24007879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":76,"alternative-id":["S0924977X24007879"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.11.013","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}